NO20013143D0 - Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med enökning av AT-1 eller AT-2 reseptorer - Google Patents

Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med enökning av AT-1 eller AT-2 reseptorer

Info

Publication number
NO20013143D0
NO20013143D0 NO20013143A NO20013143A NO20013143D0 NO 20013143 D0 NO20013143 D0 NO 20013143D0 NO 20013143 A NO20013143 A NO 20013143A NO 20013143 A NO20013143 A NO 20013143A NO 20013143 D0 NO20013143 D0 NO 20013143D0
Authority
NO
Norway
Prior art keywords
receptors
treatment
receptor
diseases associated
enhancement
Prior art date
Application number
NO20013143A
Other languages
English (en)
Other versions
NO20013143L (no
NO328775B1 (no
Inventor
Gillian Rosemary Bullock
Marc De Gasparo
Sabina Maria Ganter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013143(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20013143D0 publication Critical patent/NO20013143D0/no
Publication of NO20013143L publication Critical patent/NO20013143L/no
Publication of NO328775B1 publication Critical patent/NO328775B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20013143A 1998-12-23 2001-06-22 Komprimerte tabletter omfattende valsartan. NO328775B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98811257 1998-12-23
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
PCT/EP1999/010330 WO2000038676A1 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Publications (3)

Publication Number Publication Date
NO20013143D0 true NO20013143D0 (no) 2001-06-22
NO20013143L NO20013143L (no) 2001-08-16
NO328775B1 NO328775B1 (no) 2010-05-10

Family

ID=26152118

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20013143A NO328775B1 (no) 1998-12-23 2001-06-22 Komprimerte tabletter omfattende valsartan.
NO20100041A NO20100041L (no) 1998-12-23 2010-01-12 Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100041A NO20100041L (no) 1998-12-23 2010-01-12 Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer

Country Status (26)

Country Link
EP (3) EP1588706B1 (no)
JP (2) JP2002533390A (no)
KR (1) KR100646716B1 (no)
CN (2) CN1636561A (no)
AT (2) ATE354364T1 (no)
AU (4) AU3043000A (no)
BR (1) BR9916576A (no)
CA (2) CA2351357A1 (no)
CY (2) CY1106581T1 (no)
CZ (2) CZ297795B6 (no)
DE (1) DE69935249T2 (no)
DK (2) DK1588706T3 (no)
ES (2) ES2281978T3 (no)
HK (1) HK1038888B (no)
HU (1) HUP0104780A3 (no)
ID (1) ID29856A (no)
IL (5) IL143233A0 (no)
NO (2) NO328775B1 (no)
NZ (3) NZ587909A (no)
PL (1) PL199100B1 (no)
PT (2) PT1140071E (no)
RU (3) RU2271809C2 (no)
SI (2) SI1140071T1 (no)
SK (1) SK9132001A3 (no)
TR (7) TR200805741T2 (no)
WO (1) WO2000038676A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301390A3 (en) * 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
WO2002083127A1 (fr) * 2001-04-09 2002-10-24 Tokai University Educational System Compositions inhibant la modification proteique
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
CA2466659A1 (en) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EA008063B1 (ru) * 2003-11-03 2007-02-27 Зентива А.С. Рецептура, содержащая валсартан (valsartan)
US7795275B2 (en) * 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
WO2006066961A1 (en) 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2139473A1 (en) * 2007-03-29 2010-01-06 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
CN101888829A (zh) 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
HRP20230178T3 (hr) * 2007-11-06 2023-03-31 Novartis Ag Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep)
US20110104166A1 (en) 2008-01-18 2011-05-05 Stankovic Konstantina M Methods and Compositions for Treating Polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE68916983T2 (de) * 1988-02-25 1995-01-19 Yamanouchi Europ Bv Verfahren zur Herstellung eines pharmazeutischen Granulats.
EP0955294B1 (en) 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE19675036I2 (de) 1990-02-19 2004-10-21 Novartis Ag Acylverbindungen.
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
JP3208139B2 (ja) * 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ii▼アンタゴニスト
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
EP0872235A1 (en) 1992-04-13 1998-10-21 Zeneca Limited Therapeutic agents
US5610153A (en) 1992-12-11 1997-03-11 Ciba-Geigy Corporation Benzazepinone derivatives
US5683997A (en) * 1992-12-11 1997-11-04 Ciba-Geigy Corporation Substituted benzazepinones
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
SK117996A3 (en) 1994-03-17 1997-03-05 Ciba Geigy Ag Pharmaceutical composition for treatment of diabetic nephropathy
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
DK0853477T3 (da) 1995-10-06 2003-02-10 Novartis Ag AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
AU1791497A (en) * 1996-02-29 1997-09-16 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
EP1870098A3 (en) 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
AU766453C (en) 1999-01-26 2004-11-25 Novartis Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
HUP0301390A3 (en) * 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
WO2005039637A2 (en) 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume C型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
HUP0104780A2 (hu) 2002-04-29
NZ553010A (en) 2008-09-26
DK1588706T3 (da) 2012-01-16
PT1588706E (pt) 2011-12-21
SK9132001A3 (en) 2002-01-07
HK1038888A1 (en) 2002-04-04
RU2005124363A (ru) 2007-02-10
TR200805741T2 (tr) 2008-10-21
AU2006203077B2 (en) 2009-10-08
SI1140071T1 (sl) 2007-08-31
IL179017A0 (en) 2007-03-08
CZ297795B6 (cs) 2007-03-28
ES2281978T3 (es) 2007-10-01
BR9916576A (pt) 2001-10-02
TR200805275T2 (tr) 2008-09-22
TR200200764T2 (tr) 2002-07-22
JP2010090169A (ja) 2010-04-22
PT1140071E (pt) 2007-05-31
EP2298298A2 (en) 2011-03-23
CN1331590A (zh) 2002-01-16
ATE354364T1 (de) 2007-03-15
CZ293257B6 (cs) 2004-03-17
AU2003266433A1 (en) 2004-01-08
PL349424A1 (en) 2002-07-29
CA2351357A1 (en) 2000-07-06
PL199100B1 (pl) 2008-08-29
AU2003266433B2 (en) 2006-08-10
NO20100041L (no) 2001-08-16
CN1304000C (zh) 2007-03-14
CA2622805C (en) 2011-05-10
SI1588706T1 (sl) 2012-01-31
NO20013143L (no) 2001-08-16
IL179016A0 (en) 2007-03-08
IL143233A0 (en) 2002-04-21
RU2008143545A (ru) 2010-05-10
KR100646716B1 (ko) 2006-11-17
NZ511938A (en) 2004-02-27
TR200101784T2 (tr) 2001-10-22
EP1588706A3 (en) 2005-12-07
CN1636561A (zh) 2005-07-13
RU2361575C2 (ru) 2009-07-20
JP5254258B2 (ja) 2013-08-07
CA2622805A1 (en) 2000-07-06
CZ20012306A3 (cs) 2001-12-12
EP1140071B1 (en) 2007-02-21
EP2298298A3 (en) 2011-05-11
CY1106581T1 (el) 2012-01-25
NO328775B1 (no) 2010-05-10
DE69935249D1 (de) 2007-04-05
WO2000038676A1 (en) 2000-07-06
AU2006203077A1 (en) 2006-08-10
IL143233A (en) 2007-07-24
ES2373556T3 (es) 2012-02-06
DE69935249T2 (de) 2007-10-31
JP2002533390A (ja) 2002-10-08
AU2009220022A1 (en) 2009-10-15
ID29856A (id) 2001-10-18
EP1588706B1 (en) 2011-09-14
DK1140071T3 (da) 2007-06-04
CY1112395T1 (el) 2015-12-09
EP1588706A2 (en) 2005-10-26
TR200605472T1 (tr) 2007-02-21
HUP0104780A3 (en) 2002-11-28
TR200605471T2 (tr) 2006-11-21
KR20010089681A (ko) 2001-10-08
AU2009220022B2 (en) 2011-11-03
IL179015A0 (en) 2007-03-08
NZ587909A (en) 2012-05-25
TR200805740T1 (tr) 2010-06-21
EP1140071A1 (en) 2001-10-10
AU3043000A (en) 2000-07-31
RU2271809C2 (ru) 2006-03-20
ATE524176T1 (de) 2011-09-15
HK1038888B (zh) 2007-09-21

Similar Documents

Publication Publication Date Title
NO20013143D0 (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med enökning av AT-1 eller AT-2 reseptorer
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
BG102324A (en) Imidazole derivatives with affinity for the activity of alpha 2 receptors
DE69930308D1 (de) Selektive 5-ht 6-rezeptor-liganden
CA2386799A1 (en) Fused cycloheptane and fused azacycloheptane compounds and their as integrin receptor antagonists
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
EA200100089A1 (ru) Предотвращение рецидива мигрени
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
BR9912008A (pt) Método de tratamento
SI1148881T1 (sl) Uporaba derivatov pridazino - (4,5-(b))-indol-1-acetamida za pripravo zdravil za bolezni, povezane z disfunkcijo perifernih benzodiazepinskih receptorjev
WO2002007726A3 (en) Treatment of movement disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees